European Gram Negative AntiBacterial Engine

 

IMI

Enable

 

 

 

 

 

 

http://nd4bb-enable.eu/

Acronym:  ENABLE
Funding scheme: JTI-CP-IMI – Joint Technology Initiatives – Collaborative Project (IMI)
Call identifier: IMI-JU-08-2012
Implementation period:  01.02.2014. – 31.01.2020.
Project coordinator: GlaxoSmithKline
Project partners:

EFPIA (European Federation of Pharmaceutical Industries and Associations) companies
• GlaxoSmithKline Research and Development Ltd, Brentford, UK
• AstraZeneca AB, Sodertalje, Sweden
• Basilea Pharmaceutica AG, Basel, Switzerland
• Sanofi-Aventis Research and Development, Chilly-Mazarin, France

Universities, research   organisations, public bodies, non-profit groups
• Agencia Estatal Consejo Superior de Investigaciones Cientificas, Madrid, Spain
• Aston University, Birmingham, UK
• Cardiff University, Cardiff, UK
• European Biotechnology Network aisbl, Brussels, Belgium
• Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en      Andalucía Medina, Armilla Granada, Spain
• Helsingin Yliopisto, Helsinki, Finland
• Hvidovre Hospital, Hvidovre, Denmark
• John Innes Centre, Norwich, UK
• Københavns Universitet, Copenhagen, Denmark
Latvijas Organiskas Sintezes Instituts, Riga, Latvia
• National Medicines Institute (Narodowy Instytut Lekow), Warsaw, Poland
• Servicio Madrileno De Salud, Madrid, Spain
• SP Process Development, Södertälje, Sweden
• Stichting VU-VUMC , Amsterdam, Netherlands
• University Of Oxford, Oxford, UK
• Universitat de Barcelona, Barcelona, Spain
• University of Liege, Liege, Belgium
• Uppsala University, Uppsala, Sweden

Small and medium-sized enterprises (SMEs)
• Asclepia Outsourcing Solutions BVBA, Destelbergen, Belgium
• Beactica AB, Uppsala, Sweden
• Biomol-Informatics SL, Madrid, Spain
• Inspiralis Ltd, Norwich, UK
• KeytoLead AB, Sodertalje, Sweden
• Molecular Discovery Ltd, London, UK
• Northern Antibiotics Oy Ltd, Helsinki, Finland
• OT Chemistry, Uppsala, Sweden
• Redx Pharma Ltd, Manchester, UK
• The Research Network Ltd (TRN), UK

Leader of Latvian team: Professor Edgars Sūna
Total costs: 100 885 487 EUR
IMI funding : 58 900 000 EUR
EFPIA in kind: 22 952 360 EUR
Costs for Latvian partner: 6 065 220 EUR

Summary
Antimicrobial resistance (AMR) is a major public health threat. Infections caused by resistant bacteria are increasing and causing Europe to face soaring costs both in terms of lives and public health expenditure. Despite the strong need for new antimicrobials, very few new, effective antibiotics have been brought to the market in the last decades. The ENABLE project, within Innovative Medicines Initiative’s New Drugs for Bad Bugs (ND4BB) programme, is working to advance the development of potential antibiotics against Gram-negative bacteria, such as Escherichia coli. The ultimate goal of the project is to develop attractive antimicrobial candidates for testing in the clinic, bringing the possibility of new antibiotics to treat Gram-negative infections one step closer to patients. This collaborative project creates and manages a drug discovery platform for testing and optimising molecules.
Industry and research organisations with interesting molecules and programmes can join the ENABLE project as partners and work with a diverse range of experts in microbiology, pharmacology and chemistry to help advance their molecule through the drug development process until it is an attractive candidate for clinical testing. Programme owners retain full ownership of their molecules to ensure optimum future commercial development.
Since its launch in February 2014, ENABLE has received over 60 expressions of interest from EU-based organisations with anti-infective programmes who wish to become part of this pan-European project. Over 10 programmes were selected by the ENABLE Portfolio Management Committee (PMC) to join the consortium and novel applications will be received until 2018.
The project will focus on the discovery and pre-clinical stages of drug development, as well as (potentially) phase 1 clinical trials.

Project deliverables by 2020:
• Identication of three antibacterial lead programmes which are confirmed as having promising antimicrobial activity
• Identification of two antibacterial clinical candidate programmes for preclinical testing
• Processing at least one compound into preclinical and phase 1 clinical studies, i.e. early clinical safety testing in humans.